IQVIA
NYSE: IQV
Stock price
259.42 USD
(+0%) TODAY
Financial Performance
5Y price score: 0
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 242.8%
US$ Per
Share
By default your notes are visible only to you.
154.5
52-week range
261.8
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
5.9 %
Dividend Yield TTM
-
Market cap $
$ 42,701
Price / Earnings TTM
32.2
Price / Book TTM
7
PEG TTM
(49.6)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
38 %
0.3 %
242.8 %
Free cash flow per share growth
26.7 %
71.6 %
273.8 %
Earnings per share growth
(0.6) %
448.3 %
154.5 %
Founded: 1,982
Employees: 89,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 28, 2026)
1) Strong Financial Performance - IQVIA reported Q2 2026 revenue of $4.368 billion, up 8.7% YoY, exceeding guidance. - Adjusted EBITDA grew 9.2% YoY to $994 million. - Adjusted diluted EPS was $3.15, reflecting a 12.1% increase YoY. - Organic growth accelerated to 6%, three times the previous year’s rate.
2) Segment Highlights - R&D Solutions revenue reached $2.575 billion, up 8.8% YoY, with net new bookings of $3.15 billion, a 19% increase YoY. - Commercial Solutions revenue was $1.793 billion, up 8.6% YoY, driven by strong demand for analytics and consulting services. - The book-to-bill ratio for R&D Solutions was 1.22, indicating strong demand and operational performance.
3) Market Dynamics and Demand Trends - The clinical environment is seeing strong RFP flow growth, with double-digit increases YoY and sequentially. - Emerging biopharma (EBP) companies now represent 70% of all clinical trial starts, highlighting a shift in industry dynamics. - Increased drug launches (up 45% YoY) are driving demand for commercial solutions.
4) Operational Improvements and AI Integration - Adjusted EBITDA margins improved due to operational productivity programs, with AI contributing significantly to efficiency. - IQVIA is expanding its AI capabilities, with 294 agents deployed across 90 use cases to enhance clinical trial outcomes. - The company is focusing on integrating AI into its offerings to improve study design and patient recruitment.
5) Guidance and Future Outlook - Full-year 2026 revenue guidance raised to $17.275 billion - $17.475 billion, reflecting 5.9% to 7.1% growth. - Adjusted EBITDA guidance increased to $4 billion - $4.05 billion, with adjusted diluted EPS expected between $12.80 and $13.00. - The call did not provide specific details on the impact of FX and pass-throughs on future margins.
Bottom line: IQVIA's robust Q2 performance, driven by strong operational execution and growing demand in both clinical and commercial segments, positions the company favorably for continued growth. The raised guidance reflects confidence in sustaining this momentum, making it an attractive prospect for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteIQVIA — Financial Overview, Stock Price, Market Cap
IQVIA is a company. Founded in 1982. As of August 26, 2026, the company's market capitalization is $42700532000 with a current stock price of $259.42.